New modalities in detection of recurrent ovarian cancer

Current Opinion in Obstetrics and Gynecology

Volumn 16, Issue 1, 2004, Pages 5-9

  Tammela, Jonathan ^a   Lele, Shashikant ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Detection; Recurrent ovarian cancer; Screening

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RECURRENCE; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; DATA ANALYSIS; DIAGNOSTIC ACCURACY; HUMAN; MEDICAL LITERATURE; MOLECULAR BIOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CARCINOMA; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIODIAGNOSIS; REVIEW;

DIAGNOSTIC IMAGING; DIAGNOSTIC TECHNIQUES, OBSTETRICAL AND GYNECOLOGICAL; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 1242317079     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-200402000-00003     Document Type: Review

References (48)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics. CA Cancer J Clin 2001; 51:15-36.
2. National Institutes of Health Consensus Development Panel on Ovarian Cancer. National Institutes of Health Consensus Conference: ovarian cancer, screening, treatment and follow-up. JAMA 1995; 8:491-497.
3. Kabawat SE, Bast RC, Bhan AK, et al. Tissue distribution of a coelomic epithelium-related antigen recognized by the monoclonal antibody OC-125. Int J Gynecol Pathol 1983; 2:275-285.
4. Meyer T, Rustin GJS. Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer 2000; 82:1535-1538.
5. Pectasides D, Kayianni H, Facou A, et al. Correlation of abdominal computed tomography scanning and second-look operation findings in ovarian cancer patients. Am J Clin Oncol 1991; 14:457-462.
6. DeRosa V, Mangoni di Stefano M, Brunetti A, et al. Computed tomography and second-look surgery in ovarian cancer patients: correlation, actual role and limitations of CT scan. Eur J Gynecol Oncol 1995; 16:123-129.
7. Calkins A, Stehman F, Wass J, et al. Pitfalls in interpretation of computed tomography prior to second-took laparotomy in patients with ovarian cancer. Br J Radiol 1987; 60:975-979.
8. Pannu HK, Horton KM, Fishman EK. Thin section dual-phase multidetectorrow computed tomography detection of peritoneal metastases in gynecologic cancers. J Comput Assist Tomogr 2003; 27:333-340.
9. Prayer L, Kainz C, Kramer J, et al. CT and MR accuracy in the detection of tumor recurrence in patients treated for ovarian cancer. J Comput Assist Tomogr 1993; 17:626-632.
10. Forstner R, Hricak H, Powell CB, et al. Ovarian cancer recurrence; value of MR imaging. Radiology 1995; 196:715-720.
11. Low RN, Saleh F, Song SYT, et al. Treated ovarian cancer: comparison of MR imaging with serum CA-125 level and physical examination: a longitudinal study. Radiology 1999; 211:519-528.
12. Ricke J, Sehouli J, Hach C, et al. Prospective evaluation of contrast-enhanced MRI in the depiction of peritoneal spread in primary or recurrent ovarian cancer. Eur Radiol 2003; 13:943-949. A recent report highlighting the advantage of contrast-enhanced MRI.
13. Lieberman G, MacLean AB, Buscombe JR, et al. The clinical application of a dual head gamma camera with coincidence detection in 20 women with suspected ovarian cancer. Br J Obstet Gynaecol 2001; 108:1229-1236.
14. Kubik-Huch RA, Dorffler W, von Schulthess GK, et al. Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma. Eur Radiol 2000; 10:761-767.
15. Schröder W, Zimny M, Rudlowski C, et al. The role of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) in diagnosis of ovarian cancer. Int J Gynecol Cancer 1999; 9:117-122.
16. Römer W, Avril N, Dose J, et al. Metabolic characterization of ovarian tumors with positron-emission tomography and F-18 fluorodeoxyglucose. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1997; 166:62-68.
17. Rieber A, Nussie K, Stohr I, et al. Preoperative diagnosis of ovarian tumors with MR imaging: comparison with transvaginal sonography, positron emission tomography, and histologic findings. AJR Am J Roentgenol 2001; 177:123-129.
18. Zimny M, Siggelkow W. Positron emission tomography scanning in gynecologic and breast cancers. Curr Opin Obstet Gynecol 2003; 15:69-75. A very thorough review of the literature using this technique in gynecologic cancers.
19. Vaidya AP, Curtin JP. The follow-up of ovarian cancer. Semin Oncol 2003; 30:401-412. A comprehensive review of the evidence to support ovarian cancer surveillance.
20. Nakamoto Y, Saga T, Ishimori T, et al. Clinical value of positron emission tomography with FDG for recurrent ovarian cancer. AJR Am J Roentgenol 2001; 176:1449-1454.
21. Rose PG, Faulhaber P, Miraldi F, Abdul-Karim FW. Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy. Gynecol Oncol 2001; 82:17-21.
22. Bristow RE, Simpkins F, Pannu HK, et al. Positron emission tomography for detecting clinically occult surgically resectable metastatic ovarian cancer. Gynecol Oncol 2002; 85:196-200.
23. Makhija S, Howden N, Edwards R, et al. Positron emission tomography/ computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma: a retrospective review. Gynecol Oncol 2002; 85:53-58.
24. Zimny M, Siggelkow W, Schröder W, et al. 2-[Fluorine-18]-fluoro-2- deoxy-D-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer. Gynecol Oncol 2001; 83:310-315.
25. Yen RF, Sun SS, Shen YY, et al. Whole body positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer. Anticancer Res 2001; 21:3691-3694.
26. Torizuka T, Nobezawa S, Kanno T, et al. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose. Eur J Nucl Med Mol Imaging 2002; 29:797-803.
27. Karlan BY, Hawkins R, Hoh C, et al. Whole-body positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma. Gynecol Oncol 1993; 51:175-181.
28. Chang WC, Hung YC, Kao CH, et al. Usefulness of whole body positron emission tomography (PET) with 18F-fluoro-2-deoxyglucose (FDG) to detect recurrent ovarian cancer based on asymptomatically elevated serum levels of tumor marker (CA-125 antigen). Neoplasma 2002; 49:329-333.
29. Torizuka T, Nobezawa S, Kanno T, et al. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose. Eur J Gynecol Oncol 2002; 29:797-803.
30. Cho SM, Ha HK, Byun JY, et al. Usefulness of FDG PET for assessment of early recurrent epithelial ovarian cancer. AJR Am J Roentgenol 2002; 179:391-395.
31. Drieskens O, Stroobants S, Gysen M, et al. Positron emission tomography with FDG in the detection of peritoneal and retroperitoneal metastases of ovarian cancer. Gynecol Obstet Invest 2003; 55:130-134.
32. 18F-FDG PET. J Nucl Med 2003; 44:1051-1056. An intriguing imaging concept, specifically for pelvic tumors. Needs to be investigated further.
33. Zeisel SH. Dietary choline: biochemistry, physiology, and pharmacology. Annu Rev Nutr 1981; 1:95-121.
34. 111In- DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical results. J Nucl Med 2003; 44:700-707.
35. Wilder JL, Pavlik E, Straughn JM, et al. Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation. Gynecol Oncol 2003; 89:233-235.
36. Suzuki M, Ohwada M, Aida I, et al. Macrophage colony-stimulating factor as a tumor marker for epithelial ovarian cancer. Obstet Gynecol 1993; 82:946-950.
37. McGuckin MA, Wright G, Ward BG. Expression of a polymorphic epithelial mucin antigen defined by the monoclonal antibody BC2 in ovarian carcinoma: use of the BC2 antibody for the detection of micrometastases. Am J Clin Pathol 1991; 96:46-52.
38. Xu Y, Shen Z, Wiper D, et al. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 1998; 280:719-723.
39. Shen Z, Wu M, Elson P, et al. Fatty acid composition of lysophosphatidic acid and lysophosphatidylinositol in plasma from patients with ovarian cancer and other gynecological diseases. Gynecol Oncol 2001; 83:25-30.
40. Kim JH, Skates SJ, Uede T, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002; 287:1671-1679.
41. Temper C, Hefler L, Haeusler G, et al. Tissue polypeptide specific antigen in the follow-up of ovarian and cervical cancer patients. Int J Cancer (Pred Oncol) 1998; 79:241-244.
42. Sliutz G, Tempfer C, Kainz CH, et al. Tissue polypeptide specific antigen and cancer associated serum antigen in the follow-up of ovarian cancer. Anticancer Res 1995; 15:1127-1130.
43. Yeh LS, Hung YC, Kao A, et al. Tissue polypeptide specific antigen (TPS) and carbohydrate antigen 125 (CA-125) in the early prediction of recurrent ovarian cancer. Anticancer Res 2002; 22:3669-3672.
44. Gadducci A, Ferdeghini M, Cosio S, et al. The clinical relevance of serum CYFRA 21-1 assay in patients with ovarian cancer. Int J Gynecol Cancer 2001; 11:277-282.
45. Odunsi K, Ghamande S, Chandrasekaran EV, et al. Evaluation of beta 1,4-galactosyltransferase as a potential biomarker for the detection of subclinical disease after the completion of primary therapy for ovarian cancer. Am J Obstet Gynecol 2002; 187:575-580. The largest study completed, comparing directly a potential tumor marker with Ca 125.
46. Høgdall EVS, Johansen JS, Kjaer SK, et al. High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival. Oncol Rep 2003; 10:1535-1538.
47. Dehn H, Høgdall EVS, Johansen JS, et al. Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer. Acta Obstet Gynecol Scand 2003; 82:287-293.
48. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359:572-577. This paper has encouraged further investigations to describe the utility of this technology.